AstraZeneca has signed a licensing agreement with Chia Tai Tianqing Pharmaceutical Group (part of Sino Biopharmaceutical) for a molecule called TQC3721, an experimental treatment for Chronic Obstructive Pulmonary Disease (COPD).

With a $200 million upfront payment, and further development, regulatory and sales milestones that could take the total deal value to $1.9 billion, AstraZeneca has gained the rights to develop and commercialise the drug globally, excluding China. The agreement highlights not only the search for new treatments for one of the world's most common respiratory diseases, but also the changing landscape of pharmaceutical innovation.1

Key deal terms: Upfront payment $200m · Total potential value up to $1.9bn · Rights granted: global, excluding China · Development stage: Phase IIb COPD data reported; nebulised formulation in Phase III in China

What is TQC3721?

TQC3721 is an investigational COPD medicine that works as a dual PDE3 and PDE4 inhibitor.2

PDE3 inhibition helps relax the smooth muscles in the airways, improving airflow and making breathing easier. PDE4 inhibition reduces inflammation and mucus production within the lungs, two key contributors to COPD symptoms.

COPD is a progressive, long-term lung disease that causes breathing difficulties. It includes conditions such as emphysema, where the air sacs in the lungs become damaged, and chronic bronchitis, where the airways become inflamed and produce excess mucus. The main causes include long-term exposure to lung irritants such as cigarette smoke and chemical fumes.3

COPD affects hundreds of millions of people worldwide and remains one of the leading causes of death globally.4

TQC3721 has demonstrated encouraging Phase II results, but it still requires successful Phase III trials and regulatory approval before it can reach patients.5

Why Would AstraZeneca Pay Before Approval?

Why would AstraZeneca commit billions to a medicine that has not yet reached the market?

The answer lies in the difficulty of drug development. Creating new medicines is expensive, time-consuming and highly uncertain, with many potential treatments failing before reaching approval.

Rather than discovering every drug internally, pharmaceutical companies are increasingly partnering with smaller biotechnology firms that have already developed promising candidates. Once a molecule shows potential in early clinical trials, larger companies can license the rights and continue development, reducing the time and scientific risk involved.

AstraZeneca's deal for TQC3721 reflects this broader strategy: acquiring access to promising innovation before competitors do.

What Role Does China Play?

China has rapidly transformed from being primarily a manufacturing hub for medicines into one of the world's fastest-growing centres for biotechnology innovation.

Some reports estimate that Chinese biotechnology companies now contribute a significant proportion of the global innovative drug pipeline, driven by substantial investment, government support and an influx of scientific talent.6

China also has a major advantage in clinical research: its large population allows pharmaceutical companies to recruit patients for clinical trials at significant scale. This can help accelerate the process of testing new medicines compared with smaller markets.

Historically, global pharmaceutical innovation was concentrated in established biotechnology hubs such as Boston, San Francisco and Cambridge (UK). Today, however, companies are increasingly looking towards Shanghai, Beijing and Suzhou: not simply as commercial markets, but as sources of novel therapies.

China is no longer just a place to sell medicines: it's becoming a place to find them.

A Changing Market

The way pharmaceutical companies discover new medicines is changing. Instead of developing every drug internally, companies are increasingly partnering with smaller biotechnology firms that have already created promising treatments.

These deals allow Big Pharma to access new medicines faster, reduce the risks associated with research and development, and strengthen future drug pipelines. AstraZeneca's agreement for TQC3721 reflects this wider shift in how the pharmaceutical industry is finding its next generation of therapies.

Final Thoughts

AstraZeneca's deal extends beyond TQC3721 itself. It highlights a wider transformation in healthcare: the next generation of medicines may emerge from biotech ecosystems across the world, not only from traditional centres of innovation.

The challenge is no longer simply discovering new drugs: it is knowing where to look.

Footnotes

  1. Pharmaceutical Technology, Sino and AstraZeneca sign licence agreement for TQC3721 (opens in a new tab), 9th July 2026. ↩

  2. European Respiratory Journal, A Dose-Ranging Study of the Inhaled Dual PDE3/4 Inhibitor TQC3721 in COPD Patients (opens in a new tab), 2024 ↩

  3. Mayo Clinic, COPD - Symptoms and causes (opens in a new tab), 27th June 2026. ↩

  4. World Health Organization, Chronic obstructive pulmonary disease (COPD) (opens in a new tab), 10th June 2026. ↩

  5. Chest, Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients With COPD in China (PACER-II): A Phase 2, Multicenter, Randomized, Double-Anonymized, Placebo-Controlled Trial (opens in a new tab), He LX, Yang L, Xiao ZK, et al., 2026 Veeva Clinical Trials, A Phase II clinical trial of TQC3721 suspension for inhalation (opens in a new tab), 20th April 2025. ↩

  6. Clifford Chance, The rise of the Chinese biotech sector: How global pharmaceutical companies are responding to China's growing innovation pipeline (opens in a new tab), 26th March 2026. ↩